Metformin Reduces Repeat Mild Concussive Injury Pathophysiology.

Area of Science:

• Neuroscience
• Pharmacology
• Traumatic Brain Injury Research

Background:

• Mild traumatic brain injury (mTBI) triggers complex brain pathologies, including inflammation and metabolic dysfunction.
• Current treatments for mTBI often lack efficacy due to the multifactorial nature of the injury.
• Metformin, an anti-diabetic drug, exhibits anti-inflammatory and cell-survival properties, suggesting potential therapeutic applications beyond diabetes.

Purpose of the Study:

• To investigate the efficacy of metformin in mitigating neuropathology and functional deficits following repeat mild closed head injury (rmCHI).
• To determine if metformin administration can ameliorate white matter damage, neuroinflammation, neuronal loss, and mitochondrial dysfunction post-rmCHI.
• To assess the impact of metformin on motor and cognitive recovery after rmCHI.

Main Methods:

• Male C57Bl/6 mice were subjected to rmCHI.
• Metformin was administered acutely after each head impact.
• Histological analyses assessed white matter damage and astrogliosis.
• Immunohistochemistry identified hippocampal parvalbumin neuron loss.
• Mitochondrial function was evaluated.
• Motor and cognitive behavioral tests were performed post-treatment.

Main Results:

• Metformin treatment markedly reduced white matter damage and astrogliosis.
• A significant decrease in the loss of hippocampal parvalbumin neurons was observed.
• Metformin administration improved mitochondrial function post-injury.
• Both motor and cognitive functions were significantly enhanced after metformin treatment discontinuation.

Conclusions:

• Metformin demonstrates neuroprotective effects against repeat mild closed head injury in a mouse model.
• The drug effectively reduces key neuropathological markers and improves functional outcomes.
• These findings suggest metformin holds promise as a therapeutic agent for managing concussion and related brain injuries.